These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31090187)

  • 21. Incidence of opportunistic infections in patients with rheumatoid arthritis treated with different molecular-targeted drugs: A population-based retrospective cohort study.
    Takabayashi K; Ando F; Ikeda K; Nakajima H; Hanaoka H; Suzuki T
    Mod Rheumatol; 2023 Nov; 33(6):1078-1086. PubMed ID: 36308397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.
    Liao TL; Chen YM; Liu HJ; Chen DY
    BMJ Open; 2017 Jan; 7(1):e014032. PubMed ID: 28057661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study.
    Veetil BM; Myasoedova E; Matteson EL; Gabriel SE; Green AB; Crowson CS
    Arthritis Care Res (Hoboken); 2013 Jun; 65(6):854-61. PubMed ID: 23281295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The risk of hospitalized infection in patients with rheumatoid arthritis.
    Smitten AL; Choi HK; Hochberg MC; Suissa S; Simon TA; Testa MA; Chan KA
    J Rheumatol; 2008 Mar; 35(3):387-93. PubMed ID: 18260176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0.
    Cobo-Ibáñez T; Descalzo MÁ; Loza-Santamaría E; Carmona L; Muñoz-Fernández S
    Rheumatol Int; 2014 Jul; 34(7):953-61. PubMed ID: 24414744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database.
    Sakai R; Cho SK; Nanki T; Koike R; Watanabe K; Yamazaki H; Nagasawa H; Amano K; Tanaka Y; Sumida T; Ihata A; Yasuda S; Nakajima A; Sugihara T; Tamura N; Fujii T; Dobashi H; Miura Y; Miyasaka N; Harigai M;
    Rheumatol Int; 2014 Dec; 34(12):1729-36. PubMed ID: 24852650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Risk of Malignancy in Korean Patients with Rheumatoid Arthritis.
    Lee H
    Yonsei Med J; 2019 Feb; 60(2):223-229. PubMed ID: 30666845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis.
    Schenfeld J; Iles J; Trivedi M; Accortt NA
    Rheumatol Int; 2017 Jul; 37(7):1075-1082. PubMed ID: 28255642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization.
    Won S; Cho SK; Kim D; Han M; Lee J; Jang EJ; Sung YK; Bae SC
    Rheumatol Int; 2018 Apr; 38(4):649-656. PubMed ID: 29302803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends in Hospitalizations for Serious Infections in Patients With Rheumatoid Arthritis in the US Between 1993 and 2013.
    Jinno S; Lu N; Jafarzadeh SR; Dubreuil M
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):652-658. PubMed ID: 28732148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.
    Lacaille D; Guh DP; Abrahamowicz M; Anis AH; Esdaile JM
    Arthritis Rheum; 2008 Aug; 59(8):1074-81. PubMed ID: 18668604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: A systematic review and meta-analysis.
    Shi Y; Wu Y; Ren Y; Jiang Y; Chen Y
    Int J Rheum Dis; 2019 Aug; 22(8):1361-1370. PubMed ID: 31099191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of opportunistic infections in patients with antineutrophil cytoplasmic antibody-associated vasculitis, using a Japanese health insurance database.
    Sakai R; Tanaka E; Nishina H; Suzuki M; Yamanaka H; Harigai M
    Int J Rheum Dis; 2019 Nov; 22(11):1978-1984. PubMed ID: 31338986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.
    Cho SK; Lee J; Han M; Bae SC; Sung YK
    Arthritis Res Ther; 2017 Dec; 19(1):277. PubMed ID: 29246243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review.
    Downey C
    Int J Rheum Dis; 2016 Jun; 19(6):536-50. PubMed ID: 26200188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential risk of herpes zoster infection with biologic agent use in rheumatoid arthritis: comment on the article by Yun et al.
    Ranganathan P
    Arthritis Care Res (Hoboken); 2015 Jul; 67(7):1041. PubMed ID: 25470792
    [No Abstract]   [Full Text] [Related]  

  • 37. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
    Curtis JR; Xie F; Yun H; Bernatsky S; Winthrop KL
    Ann Rheum Dis; 2016 Oct; 75(10):1843-7. PubMed ID: 27113415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of Herpes Zoster in Patients With Rheumatoid Arthritis in the United States: A Retrospective Cohort Study.
    Singer D; Thompson-Leduc P; Poston S; Gupta D; Cheng WY; Ma S; Devine F; Duh MS; Curtis JR
    J Rheumatol; 2023 Jul; 50(7):873-880. PubMed ID: 36725054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coxiella burnetii infection (Q fever) in rheumatoid arthritis patients with and without anti-TNFα therapy.
    Schoffelen T; Kampschreur LM; van Roeden SE; Wever PC; den Broeder AA; Nabuurs-Franssen MH; Sprong T; Joosten LA; van Riel PL; Oosterheert JJ; van Deuren M; Creemers MC
    Ann Rheum Dis; 2014 Jul; 73(7):1436-8. PubMed ID: 24794150
    [No Abstract]   [Full Text] [Related]  

  • 40. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F; Michaud K
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.